LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 71

Search options

  1. Article: Vascular Involvement in Behcet's Disease: An Evaluation of 147 Cases and Literature Review.

    Atalar, Ebru / Erten, Sukran / Dogan, Ismail / Konak, Hatice Ecem

    Sisli Etfal Hastanesi tip bulteni

    2023  Volume 57, Issue 3, Page(s) 380–386

    Abstract: Objectives: Behcet's disease (BD) is characterized by systemic vasculitis with inflammation that can affect various body organs. In BD, vasculitis primarily manifests with venous involvement, distinguishing it from other forms of systemic vasculitis.: ...

    Abstract Objectives: Behcet's disease (BD) is characterized by systemic vasculitis with inflammation that can affect various body organs. In BD, vasculitis primarily manifests with venous involvement, distinguishing it from other forms of systemic vasculitis.
    Methods: We retrospectively analyzed the demographic and clinical characteristics of 147 patients diagnosed with vascular BD in our center.
    Results: Vascular BD cases accounted for 25.0% (147 out of 589) of all BD patients. A statistically significant correlation was found between gender and vascular involvement that was seen predominantly in males (76.9%). In 71 patients, a vascular event developed during follow-up for BD, while in 76 patients the disease was diagnosed after the occurrence of a vascular event (51.7%). The most common vascular event was deep vein thrombosis in the lower extremities (69.4%). Arterial involvement was primarily observed in the pulmonary arteries (12.9%). Patients with lower extremity deep vein thrombosis tended to be younger, while those with pulmonary artery involvement were typically older. Overall, veins were affected 4.5 times more frequently than arteries.
    Conclusion: The prevalent type of venous involvement was deep vein thrombosis in the lower extremities. Thrombotic events in BD cannot be solely attributed to abnormalities in thrombotic factors. The treatment of thrombotic events in BD remains contentious, with anticoagulant efficacy being debated and immunosuppressive therapy representing the primary treatment approach. Behcet's disease should be considered when a young male patient presents with an arterial or venous vascular event, especially if it is recurrent.
    Language English
    Publishing date 2023-09-29
    Publishing country Turkey
    Document type Journal Article
    ZDB-ID 3026862-X
    ISSN 1308-5123 ; 1302-7123
    ISSN (online) 1308-5123
    ISSN 1302-7123
    DOI 10.14744/SEMB.2023.89083
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Secukinumab can treat psoriasis induced by anti-TNF-alpha therapy in patients with ankylosing spondylitis: Case series.

    Apaydin, Hakan / Dogan, Ismail / Erten, Şükran

    International journal of rheumatic diseases

    2020  Volume 23, Issue 3, Page(s) 454–456

    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; Female ; Humans ; Middle Aged ; Psoriasis/chemically induced ; Psoriasis/diagnosis ; Psoriasis/drug therapy ; Psoriasis/immunology ; Remission Induction ; Spondylitis, Ankylosing/diagnosis ; Spondylitis, Ankylosing/drug therapy ; Spondylitis, Ankylosing/immunology ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors/adverse effects
    Chemical Substances Antibodies, Monoclonal, Humanized ; Tumor Necrosis Factor Inhibitors ; secukinumab (DLG4EML025)
    Language English
    Publishing date 2020-01-15
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 2426924-4
    ISSN 1756-185X ; 1756-1841
    ISSN (online) 1756-185X
    ISSN 1756-1841
    DOI 10.1111/1756-185X.13791
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: 14-3-3η Proteins as a Diagnostic Marker, Disease Activation Indicator, and Lymphoma Predictor in Patients with Primary Sjögren Syndrome.

    Kor, Ahmet / Yalçın, Merve / Erten, Şükran / Maraş, Yüksel / Oğuz, Esra Fırat / Doğan, İsmail / Atalar, Ebru / Başer, Salih / Erel, Özcan

    Archives of Iranian medicine

    2023  Volume 26, Issue 10, Page(s) 582–591

    Abstract: Background: Primary Sjögren syndrome (PSS) is a chronic, autoimmune, and lymphoproliferative disease of the connective tissue. In patients with PSS, the risk of developing B-cell non-Hodgkin lymphoma (NHL) increases dramatically, with a prevalence of ... ...

    Abstract Background: Primary Sjögren syndrome (PSS) is a chronic, autoimmune, and lymphoproliferative disease of the connective tissue. In patients with PSS, the risk of developing B-cell non-Hodgkin lymphoma (NHL) increases dramatically, with a prevalence of approximately 5%. The 14-3-3 protein isoforms are phospho-serin/phospho-threonine binding proteins associated with many malignant diseases. This study aimed to evaluate the relationship between disease activity parameters and markers predicting lymphoma development in patients with PSS and 14-3-3η proteins.
    Methods: This study was designed as an analytical case-control study. A total of 57 PSS patients and 54 healthy volunteers were included in the study. The European League Against Rheumatism (EULAR) Sjögren syndrome disease activity index (ESSDAI) was used to assess systemic disease activity in PSS. Receiver operating characteristic (ROC) analysis was used to test the diagnostic accuracy measures of the analytical results. Multivariable linear regression analysis was used to evaluate the effects of independent variables on the 14-3-3η protein.
    Results: The 14-3-3η protein serum levels were found to be significantly higher in PSS (2.72 [2.04-4.07]) than healthy controls (1.73 [1.41-2.43]) (
    Conclusion: 14-3-3η proteins are potential candidates for diagnostic marker, marker of disease activity, and predictor of lymphoma in PSS patients.
    MeSH term(s) Humans ; Sjogren's Syndrome/complications ; Sjogren's Syndrome/diagnosis ; Case-Control Studies ; 14-3-3 Proteins ; Lymphoma/diagnosis ; Lymphoma/epidemiology
    Chemical Substances 14-3-3 Proteins
    Language English
    Publishing date 2023-10-01
    Publishing country Iran
    Document type Journal Article
    ZDB-ID 2204979-4
    ISSN 1735-3947 ; 1029-2977
    ISSN (online) 1735-3947
    ISSN 1029-2977
    DOI 10.34172/aim.2023.85
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: 14-3-3 η ETA protein as a potential marker of joint damage in gout.

    Doğan, İsmail / Kor, Ahmet / Güven, Serdar Can / Fırat Oğuz, Esra / Başer, Salih / Atalar, Ebru / Maraş, Yüksel / Erel, Özcan / Erten, Şükran

    Clinical biochemistry

    2023  Volume 118, Page(s) 110611

    Abstract: Introduction: The aim of the study is to investigate serum levels of 14-3-3 η (ETA) protein in patients with gout and possible relations with joint damage.: Method: This cross-sectional study included 43 gout patients and 30 control patients.: ... ...

    Abstract Introduction: The aim of the study is to investigate serum levels of 14-3-3 η (ETA) protein in patients with gout and possible relations with joint damage.
    Method: This cross-sectional study included 43 gout patients and 30 control patients.
    Results: Serum 14-3-3 η protein levels were significantly higher in gout patients (median [IQR], 3.1 [2.0] vs 2.2 [1.0], p = 0.007). In subgroup analyses of gout patients, serum 14-3-3 η protein levels did not differ between patients with and without a flare, tophaceous disease, elevated CRP and serum uric acid levels and a history of chronic kidney disease; however, were significantly higher in the patients with erosions (Median [IQR], 4.1 [2.7] vs 2.7 [1.5], p = 0.002). According to ROC curve, serum 14-3-3 η protein had 86.0% sensitivity and 30% specifity at a cut-off point of 1.7 ng/mL and had 74.7% sensitivity and 43.3% specifity at a cut-off point of 2.0 ng/mL.
    Conclusion: Our results demonstrated elevated levels of 14-3-3 η protein in gout patients which is more prominent in patients with erosive changes, implying role of 14-3-3 η protein in inflammatory and structural damage related pathways and suggesting a potential as a marker for disease severity.
    MeSH term(s) Humans ; Uric Acid ; 14-3-3 Proteins ; Cross-Sectional Studies ; Gout/diagnosis ; ROC Curve
    Chemical Substances Uric Acid (268B43MJ25) ; 14-3-3 Proteins
    Language English
    Publishing date 2023-07-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 390372-2
    ISSN 1873-2933 ; 0009-9120
    ISSN (online) 1873-2933
    ISSN 0009-9120
    DOI 10.1016/j.clinbiochem.2023.110611
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: [No title information]

    Dogan, İsmail / Güven, Serdar Can / Karakaş, Özlem / Erdoğan, Esra Kayacan / Erten, Sukran

    Aktuelle Rheumatologie

    2023  Volume 48, Issue 06, Page(s) 389–394

    Abstract: Objective: To evaluate the adherence to colchicine treatment during pregnancy and lactation in our Familial Mediterranean fever (FMF) patients and investigate the reasons for non-adherence and consequences.: ... ...

    Abstract Objective: To evaluate the adherence to colchicine treatment during pregnancy and lactation in our Familial Mediterranean fever (FMF) patients and investigate the reasons for non-adherence and consequences.
    Methods: Adult female FMF patients who were followed up in our rheumatology clinic and had a history of pregnancy after the diagnosis of FMF were consecutively enrolled to this cross-sectional study between November 2021 and June 2022. Only pregnancies occurring after the diagnosis of FMF were evaluated. Patients who did not stop using FMF treatment after pregnancy were considered to adhere to treatment.
    Results: In 50 patients, a total of 88 pregnancies and 58 live births were observed after the diagnosis of FMF. 37 (74%) had at least one completed pregnancy, and 13 (26.0) were pregnant during the study. Among the 37 patients, 34 had at least one live birth. No significant differences were observed when rates of patients with a history of at least one live birth, abortus, Cesarean section (C/S), preterm labor, stillbirth, intrauterine anomaly, congenital malformation and fetal growth retardation were compared between colchicine users and non-users. 60% of the patients adhered to colchicine treatment during pregnancy and 73.4% did so while breastfeeding. The most common reason for colchicine cessation was concerns regarding potential harm to the fetus (70%), followed by the presumption that colchicine is contraindicated in pregnancy (15%) as well as absence of FMF attacks (10%). The most common source of the patients’ opinion was a physician (60%).
    Conclusions: Both patients and attending physicians should be informed to be more adherent to colchicine to avoid adverse outcomes and FMF-related complications.
    Keywords Familial Mediterranean fever ; pregnancy ; lactation ; medication adherence ; Familiäres Mittelmeerfieber ; Schwangerschaft ; Stillzeit ; Medikamentenhaftung
    Language English
    Publishing date 2023-04-12
    Publisher Georg Thieme Verlag
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 131267-4
    ISSN 1438-9940 ; 0341-051X
    ISSN (online) 1438-9940
    ISSN 0341-051X
    DOI 10.1055/a-2021-7668
    Database Thieme publisher's database

    More links

    Kategorien

  6. Article: [No title information]

    Karakaş, Özlem / Dogan, İsmail / Güven, Serdar Can / Erel, Şule / Erten, Sukran

    Aktuelle Rheumatologie

    2023  Volume 49, Issue 01, Page(s) 49–53

    Abstract: Background: We aimed to investigate the rate of TBC reactivation in patients with autoinflammatory conditions who had been followed up under treatment with IL-1 antagonists in our clinic. We further aimed to ... ...

    Abstract Background: We aimed to investigate the rate of TBC reactivation in patients with autoinflammatory conditions who had been followed up under treatment with IL-1 antagonists in our clinic. We further aimed to evaluate whether latent TBC screening and isoniazid prophylaxis before IL-1 inhibitor treatment is beneficial in the prevention of reactivation.
    Patients and Methods: This study was designed as a cross-sectional and observational study. It received the approval of the local ethics committee and was therefore performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Adult patients who had been followed up in our clinic under treatment with IL-1 antagonists were evaluated with regard to whether they had a TBC infection before and after these treatments and whether they had been screened for latent TBC infection before IL-1 antagonist treatment and received prophylaxis. Clinical and laboratory data were obtained from hospital records and via telephone interviews after the patients had given their verbal consent to participate.
    Results: Fifty-nine patients under IL-1 antagonists were consecutively enrolled. 58 were under follow-up with the diagnosis of familial Mediterranean fever and one patient with a diagnosis of adult-onset Still’s disease. 35 patients (59.3%) were treated with anakinra and 24 (40.7%) were treated with canakinumab. 12 (50%) of the canakinumab users had previously received anakinra treatment and were switched to canakinumab due to side-effects or ineffectiveness. The number of patients who underwent latent tuberculosisc infection (LTBI) screening before treatment was 37 (62.7%); the number of patients who received prophylaxis was 13 (22%). None of the patients receiving IL-1 antagonists developed active tuberculosis.
    Conclusion: Blocking the IL-1 pathway may be safe regarding the activation of LTBI or development of a new tuberculosis infection even in locations with a high geographical risk.
    Keywords tuberculosis ; familial Mediterranean fever ; reactivation ; autoinflammatory ; interleukin-1 ; tuberkulose ; familiäres Mittelmeerfieber ; interleukin 1 ; reaktivierung ; autoinflammatorisch
    Language English
    Publishing date 2023-03-15
    Publisher Georg Thieme Verlag
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 131267-4
    ISSN 1438-9940 ; 0341-051X
    ISSN (online) 1438-9940
    ISSN 0341-051X
    DOI 10.1055/a-2015-2683
    Database Thieme publisher's database

    More links

    Kategorien

  7. Article: [No title information]

    Dogan, İsmail / Güven, Serdar Can / Karakaş, Özlem / Erdoğan, Esra Kayacan / Erten, Sukran

    Aktuelle Rheumatologie

    2023  Volume 48, Issue 06, Page(s) e1–e1

    Language German
    Publishing date 2023-11-02
    Publisher Georg Thieme Verlag
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 131267-4
    ISSN 1438-9940 ; 0341-051X
    ISSN (online) 1438-9940
    ISSN 0341-051X
    DOI 10.1055/a-2189-8554
    Database Thieme publisher's database

    More links

    Kategorien

  8. Article ; Online: Effects of intrauterine device use on attack frequency and severity ın woman of reproductive age with familial Mediterranean fever.

    Özdemir Ulusoy, Bahar / Güven, Serdar Can / Babaoğlu, Hakan / Ulusoy, Can Ozan / Armağan, Berkan / Kayacan Erdoğan, Esra / Maraş, Yüksel / Doğan, İsmail / Orhan, Kevser / Koçak Ulucaköy, Rezan / Atalar, Ebru / Omma, Ahmet / Küçükşahin, Orhan / Erten, Şükran

    Archives of gynecology and obstetrics

    2024  Volume 309, Issue 5, Page(s) 2041–2046

    Abstract: Aim: Familial Mediterranean fever (FMF) is the most common inherited autoinflammatory disease in the world. There are known triggers to initiate an FMF attack, yet potential effects of intrauterine devices (IUD) in women of reproductive age have not ... ...

    Abstract Aim: Familial Mediterranean fever (FMF) is the most common inherited autoinflammatory disease in the world. There are known triggers to initiate an FMF attack, yet potential effects of intrauterine devices (IUD) in women of reproductive age have not been evaluated before.
    Method: Consecutive female patients with FMF who ever used IUD over the age of 18 were enrolled. Female patients with FMF were sub grouped according to the type of IUD they use. FMF attack frequency, severity, duration, presence of dysmenorrhea, severity of dysmenorrhea, having attacks during menstruation before and after IUD use were questioned. Demographic and clinical data were collected from hospital database.
    Results: When all patients with IUD use were evaluated, it was found that the frequency of attacks increased after IUD insertion at 3rd and 12th months (median [min-max] attack frequency at 3rd month, 1 (0-3) vs 1 (0-6), p = 0.002, median [min-max] attack frequency at 12th month, 2 (0-12) vs 3.5 (0-18), p = 0.028). Attack severity measured by VAS pain was also significantly increased. Attack duration and menstrual pain was similar before and after IUD use. Attack frequency at 3rd and 12th months, attack severity and menstrual pain was all increased significantly in Cu-IUD users, whereas none of these parameters deteriorated in LNG-IUD group.
    Conclusion: IUD use, especially Cu-IUD, may increase the frequency and severity of attacks in female patients with FMF. Clinicians may benefit from considering LGN-IUD if IUDs are preferred as contraception in women of childbearing age with FMF.
    MeSH term(s) Female ; Humans ; Adult ; Middle Aged ; Dysmenorrhea/etiology ; Familial Mediterranean Fever/complications ; Intrauterine Devices/adverse effects ; Contraceptive Agents, Female ; Contraception ; Intrauterine Devices, Copper/adverse effects
    Chemical Substances Contraceptive Agents, Female
    Language English
    Publishing date 2024-03-13
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 896455-5
    ISSN 1432-0711 ; 0932-0067
    ISSN (online) 1432-0711
    ISSN 0932-0067
    DOI 10.1007/s00404-024-07413-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Elevated Kynurenine Levels in Patients with Primary Sjögren's Syndrome.

    Apaydın, Hakan / Koca Bicer, Cemile / Feyza Yurt, Emine / Abdulkadir Serdar, Muhittin / Dogan, İsmail / Erten, Sukran

    Laboratory medicine

    2022  Volume 54, Issue 2, Page(s) 166–172

    Abstract: Objective: We aimed to investigate the plasma levels of tryptophan (Trp) and its metabolites in patients with primary Sjögren's syndrome (pSS).: Methods: The study included 34 pSS patients and 42 healthy individuals, and serum Trp and kynurenine (Kyn) ...

    Abstract Objective: We aimed to investigate the plasma levels of tryptophan (Trp) and its metabolites in patients with primary Sjögren's syndrome (pSS).
    Methods: The study included 34 pSS patients and 42 healthy individuals, and serum Trp and kynurenine (Kyn) concentrations were measured by liquid chromatography with tandem mass spectrometry. Trp degradation was predicted using the ratio of Kyn and Trp concentrations (Kyn/Trp).
    Results: In our study, the mean serum Trp concentration was found to be considerably lower in the pSS group than in the control group (P = .001). The levels of Kyn (P = .019) and the Kyn/Trp ratio (P < .001) were significantly higher in the pSS group than in the control group. The Kyn/Trp ratio was negatively correlated with C-reactive protein (r = -0.369, P = .032).
    Conclusion: We found that Kyn pathway metabolism was altered in patients with pSS. This suggests that Trp metabolism may be closely linked to the disease pathogenesis of pSS.
    MeSH term(s) Humans ; Kynurenine/metabolism ; Sjogren's Syndrome ; Tryptophan/metabolism ; C-Reactive Protein ; Chromatography, Liquid
    Chemical Substances Kynurenine (343-65-7) ; Tryptophan (8DUH1N11BX) ; C-Reactive Protein (9007-41-4)
    Language English
    Publishing date 2022-09-02
    Publishing country England
    Document type Journal Article
    ZDB-ID 391758-7
    ISSN 1943-7730 ; 0007-5027
    ISSN (online) 1943-7730
    ISSN 0007-5027
    DOI 10.1093/labmed/lmac084
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The effectiveness of anti-interleukin-1 therapy on subclinical inflammation parameters during the attack-free period in familial Mediterranean fever patients: A case-control study.

    Atalar, Ebru / Doğan, İsmail / Gök, Kevser / Güven, Serdar Can / Maraş, Yüksel / Ceylan, Gülay Güleç / Erten, Sükran

    Turkish journal of medical sciences

    2022  Volume 52, Issue 2, Page(s) 522–523

    Abstract: Background: : Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance, however, it is not certain whether subclinical inflammation can sufficiently be inhibited with anti-IL-1 therapy in FMF patients with ... ...

    Abstract Background: : Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance, however, it is not certain whether subclinical inflammation can sufficiently be inhibited with anti-IL-1 therapy in FMF patients with amyloidosis.
    Methods: Forty-six FMF patients receiving anti-interleukin-1 therapy and 36 healthy control patients were compared in terms of laboratory parameters. Also, FMF patients were further divided into two groups; those with amyloidosis and those without it, and these subgroups were compared to each other in terms of clinical and laboratory findings.
    Results: In comparison between the FMF and healthy control groups, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and red cell distribution width (RDW) level were detected to be higher and hemoglobin level lower in the patient group. Within the FMF patient group, the ESR, CRP, fibrinogen, RDW, and NLR values were significantly higher in the subgroup with amyloidosis in comparison to the subgroup without amyloidosis.
    Discussion: Anti-interleukin-1 therapy could not fully suppress the subclinical inflammatory parameters when compared to healthy individuals.
    MeSH term(s) Amyloidosis/chemically induced ; Amyloidosis/drug therapy ; C-Reactive Protein/analysis ; Case-Control Studies ; Colchicine/therapeutic use ; Familial Mediterranean Fever/drug therapy ; Fibrinogen ; Hemoglobins ; Humans ; Inflammation
    Chemical Substances Hemoglobins ; Fibrinogen (9001-32-5) ; C-Reactive Protein (9007-41-4) ; Colchicine (SML2Y3J35T)
    Language English
    Publishing date 2022-04-14
    Publishing country Turkey
    Document type Journal Article
    ZDB-ID 1183461-4
    ISSN 1303-6165 ; 1300-0144
    ISSN (online) 1303-6165
    ISSN 1300-0144
    DOI 10.55730/1300-0144.5338
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top